

**THE HATTER  
CARDIOVASCULAR  
INSTITUTE, UCL**

**\*WEBINAR\***



***SGLT2 INHIBITORS & GLP-1  
ANALOGUES IN THE  
MANAGEMENT OF TYPE 2  
DIABETES AND CARDIO-RENAL  
DISEASE***

***FOR TRAINEES:***

***\*CARDIOLOGY  
\*DIABETES  
\*NEPHROLOGY***

**PRESENTATIONS**

***1. Management of T2D – out with the old & in with the new!***

Prof Stephanie Baldeweg – University College London

***2. New anti-diabetic therapy - their role in renal protection.***

Prof David Wheeler - University College London

***3. The GLP-1 analogues – their role in obesity.***

Prof John Wilding – University of Liverpool

***4. SGLT2 inhibitors – their role in heart failure.***

Prof Theresa McDonagh – Kings College London

***5. SGLT2 inhibitors & GLP-1 analogues – do we understand the mechanisms?***

Dr Robert Bell - University College London

**WHEN**

**19<sup>th</sup> March, 2021**

**10am – 12noon GMT**

**REGISTER**

[https://ucl.zoom.us  
/meeting/register/t  
JAtd-  
trToiEtRPj91GyS2xO  
zwN05ukUgkD](https://ucl.zoom.us/j/9191919191)

**CHAIRS**

**Prof Derek Yellon**

**Prof John Cunningham**

**Prof Stephanie Baldeweg**

**Conclusions from SpR's in each field:**

Dr Sarah Qian (SpR in Diabetes)

Dr Ali Rauf (SpR in Cardiology)

Dr Tamer Rezk (SpR in Nephrology)



*We are grateful for the support of Novo Nordisk, AstraZeneca and Boehringer Ingelheim.  
All companies have had no influence in the selection of speakers or content of the webinar.*